RCUS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
9.0M
-78.0%
41.0M
+141.2%
17.0M
-48.5%
33.0M
+26.9%
26.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.0M
-78.0%
41.0M
+141.2%
17.0M
-48.5%
33.0M
+26.9%
26.0M
Operating Expenses
140.0M
+2.2%
137.0M
-9.3%
151.0M
+2.7%
147.0M
-12.5%
168.0M
R&D
117.0M
+3.5%
113.0M
-7.4%
122.0M
+0.8%
121.0M
-14.2%
141.0M
SG&A
23.0M
-4.2%
24.0M
-17.2%
29.0M
+11.5%
26.0M
-3.7%
27.0M
Operating Income
-131000000
-36.5%
-96000000
+28.4%
-134000000
-17.5%
-114000000
+19.7%
-142000000
EBITDA
-129000000
-38.7%
-93000000
+29.5%
-132000000
-18.9%
-111000000
+20.7%
-140000000
Net Income
-128000000
-40.7%
-91000000
+28.9%
-128000000
-20.8%
-106000000
+21.5%
-135000000
EPS (Basic)
$-1.00
-38.9%
$-0.72
+29.4%
$-1.02
-14.6%
$-0.89
+29.9%
$-1.27
EPS (Diluted)
$-1.00
-38.9%
$-0.72
+29.4%
$-1.02
-13.3%
$-0.90
+29.1%
$-1.27
Shares (Diluted)
127.4M
+1.0%
126.1M
+0.6%
125.4M
+6.1%
118.2M
+11.0%
106.5M
Arcus Biosciences (RCUS) — Financials